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                  A  centennial  is  a  good  time  to  reflect  on  history,  and  his-
tory reveals just how much progress has been made in the het-
erogeneous field of tropical medicine in the past one hundred 
years. However, the picture might look different if we start 
from the point of view of the Haitian poor. From that perspec-
tive, the rubric “tropical medicine,” coined to refer to a host 
of pathologies, has less to do with latitude than with persistent 
poverty. 
  “The white man’s grave,” one of the tropics’ sorry monikers, 
is a case in point:   this expression rose to prominence during 
the waves of European ventures into Africa, Asia, and Latin 
America. Haiti fits into such a framework because of its his-
tory, rather than its geographical coordinates. When Napoleon’s 
brother-in-law, General Charles Leclerc, set sail to reclaim 
rebellious Haiti for the French, he headed the largest armada 
ever to cross the Atlantic. But Haiti was not to be retaken. 
Leclerc’s troops encountered not only a slave uprising but also 
yellow fever, malaria, and other “tropical” scourges, as had 
Christopher Columbus, who helped establish the first European 
settlement in the New World on the northern coast of the island 
more than two centuries before. (Of course, the lethality of the 
Columbian exchange went primarily in the other direction.) 
  The colonial experience remains the template for modern 
tropical medicine. It’s a long way from colonial (and neoco-
lonial) medicine to international health, to say nothing of 
“global health”—the newest iteration of tropical medicine, 
and the best. However, it is a trajectory well worth under-
standing. The Panama Canal was one of the midwives of 
international health: the tens of thousands of workers who 
perished to yellow fever and malaria and other afflictions led 
to the establishment of the Pan-American Sanitation Bureau 
in 1902.  1   After a dozen or so such commissions on “sanitation 
and hygiene” came the effort to eradicate hookworm in 1909, 
funded by John D. Rockefeller and his foundation, which is 
also celebrating its centennial this year.  2,  3   Most public health 
initiatives in the early twentieth century focused on the appli-
cation of lessons learned and of new tools—effective and 
ineffective—such as vaccines and other preventative mea-
sures (ranging from improved hygiene to vector control), to 
the pressing health problems of the day. 
  New frontiers in tropical medicine required not only new 
preventatives, but also new diagnostics and therapeutics. The 
middle of the twentieth century was a time of rising expec-
tations, in part because of the development of effective anti-
bacterials and antiparasitics, linked to modern microbiology.  4  
Some of these new drugs and vaccines were nothing less than 
“magic bullets,” saving lives that would previously have been 
beyond recall.  5–7         Mid-century yaws, polio, measles, rubella, and 
pertussis control campaigns showcased the faith generated 
by such new tools. The pride—some would say hubris—
accompanying these developments was only strengthened by 
the eradication of smallpox in 1977.  8  
  But pride and hubris are not the same thing. If medicine is, 
to use Lewis Thomas’s felicitous expression, “the youngest sci-
ence,” then how might we apply the fruits of basic science to 
the neglected diseases of poverty?  9,  10   
  It’s not merely polemic to note that all diseases that affect 
primarily the poor are, by definition, neglected. Cholera offers 
an object lesson: one hundred fifty years after John Snow took 
the handle off the Broad Street pump, more than a century after 
his suspicions of bacterial origin were confirmed, 60 years after 
antibiotic therapy was discovered, and 30 years after a safe and 
effective oral vaccine was developed, cholera remains—among 
the world’s poorest—a leading infectious killer. 
  How could this be? How, in the 21st century, does a scourge 
against which we have a full arsenal of preventatives and ther-
apeutics continue to fell hundreds of thousands of people 
every year? Four decades after we had every tool needed to 
wipe cholera off the face of the earth, it has prospered, and, 
in the least water-secure country in the Americas, exploded 
like a bomb. The cholera epidemic in Haiti, an island nation of 
ten million, is the world’s largest in recent history: in its first 
year, cholera claimed some 6,500 lives and caused half a mil-
lion cases.  11  (And these are official numbers, which are almost 
certainly too low because there is little reporting capacity 
in rural areas, where the disease struck first and hardest.) 
  If we know so much about cholera, its pathophysiology 
and epidemiology and treatment and prevention, how did it 
become the leading infectious killer of young adults in Haiti 
during the international humanitarian response–one of the 
largest in history–to the January 2010 earthquake? The short 
answer is that expectations are lowered for diseases that dis-
proportionately afflict poor people. Investment in long-term 
public-sector water and sanitation systems have stalled or 
failed to keep up with demand. Safe, effective, and affordable 
oral vaccines exist, and yet remain unavailable in Haiti—as 
do, too often, timely diagnosis and care. When some suggested 
integrating vaccination into the response,  12   public health offi-
cials were quick to note that vaccination was not cost-effective 
(as if “cost” were fixed in stone and “effectiveness” well 
understood). Some dismissed the idea as a “trial,” as if the 
vaccine had not been tested. (It had, in fact, been tested and 
proven effective in large trials in India, Vietnam, Bangladesh, 
Mozambique, and elsewhere.  13  ) Others wrote off the feasibility 
of vaccination during the chaos of a post-earthquake epidemic. 
But Haiti’s best resource is arguably its network of commu-
nity health workers who were rapidly mobilized to dissemi-
nate information and distribute millions of water purification 
tablets in the first month of the epidemic. Robust public-sector 
water and sanitation systems must be designed and con-
structed, and are without a doubt the ultimate bulwark against 
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cholera and other waterborne diseases. However, they take 
time to build, and are not acceptable as the sole emergency 
response plan. 
  This is the dilemma of global health in the 21st century: 
finally, we have the tools for prevention and diagnosis and 
care;   what we lack is an equity plan linked to a delivery system.  
Future historians of tropical medicine may regard the first 
decade of the century (and the millennium) as the golden age 
of global health. From the time of the eradication of smallpox 
in 1977 to the end of the century, there were too few global 
health successes. But the establishment of the Bill & Melinda 
Gates Foundation, which invested in discovery and develop-
ment, and the President’s Emergency Plan for AIDS Relief 
and the Global Fund to Fight AIDS, Tuberculosis, and Malaria, 
which invested in delivery, offers a blueprint for global health 
equity. The development of a veritable delivery science should 
be the chief objective of tropical medicine. 
 Whether we look at cholera or lymphatic filariasis or malaria 
or any other “neglected tropical disease,” the roadmap for the 
future of tropical medicine and hygiene—two 19th century 
constructs—is the same: scientific discovery linked to product 
development and, most importantly, to an equitable delivery 
strategy. Only a comprehensive and integrated approach will 
sustain and broaden the achievements of the golden age of 
global health. 
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